




HEOR and Medical Access



# Health Economics & Outcomes Research and Medical Access Fellowships

2022-2024



# Novartis is a world leader in the research and development of products to protect and improve health and well-being.

Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz. Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing, and marketing prescription drugs to prevent and cure diseases, to ease suffering and to enhance quality of life. Novartis' portfolio of products is directed toward cardiovascular, multiple sclerosis, immunology, hepatology, and dermatology, organ transplantation, ophthalmology, oncology and hematology, and other therapeutic areas.

Novartis, derived from the Latin *novae artes*, meaning “new skills,” is committed to using new skills to improve health and well-being through innovative products and services. Recognizing an increasing need for outcomes information, resources and expertise, the Health Economics & Outcomes Research (HEOR) departments at Novartis strive to be best-in-class in the generation of outcomes evidence that demonstrates value and optimizes patient access to Novartis products. This is accomplished through execution of burden

and cost-of-illness studies, economic evaluations alongside clinical trials, comparative effectiveness research, cost-effectiveness analyses, prospective observational studies such as effectiveness registries, retrospective claims database analyses and patient-reported outcomes research.



## Purpose

The Health Economics & Outcomes Research (HEOR) and Medical Access Fellowship Program provides training and hands-on experience in a broad range of health economics, outcomes research and comparative effectiveness research (CER) opportunities. This 2-year program is structured to allow the Fellows to gain proficiency in the field of health economics, outcomes research and CER as conducted in academic, managed care, hospital, health policy and/or pharmaceutical industry settings.



## Overview

Novartis Pharmaceuticals Corporation is pleased to offer two 2-year Health Economics & Outcomes Research (HEOR) and Medical Access Fellowship positions for the 2022-2024 cycle.

The objective of the first year is to educate the fellow on general principles and methods applied in health economics and outcomes research. Concurrently, the fellow will participate in ongoing outcomes research projects at the first year fellowship site. All Fellows will spend the second year of the Fellowship at the US-based headquarters of Novartis Pharmaceuticals Corporation located in East Hanover, New Jersey.

While at Novartis, "field-based" training will be undertaken as part of the Fellowship training. Fellows will participate in health economics and outcomes research projects and gain experience in how a pharmaceutical manufacturer uses clinical, economic, and humanistic data to support the development and commercialization of its products, with opportunities in neuroscience, respiratory, ophthalmology, immunology, dermatology, cardiovascular, and transplant franchises.


In addition, a unique 3-6 month rotational opportunity will also be available in Medical Access, where the fellow will gain experience in "value translation" to national and regional payer accounts. The fellow will help identify strategic trends in the external payer and health plan environment that may impact access to and reimbursement for Novartis' products.

The fellowship positions differ by first-year site requirements and type of experience offered. Each position is described in this brochure. Compensation includes a competitive stipend, basic medical insurance, holiday and vacation time, plus other benefits associated with each specific academic/managed care institution.

## First-Year Fellowship Sites for 2-Year Programs:

- Baylor Scott & White Health, Temple, TX/The University of Texas at Austin, Austin, TX
- Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA
- Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD (not recruiting 2022-2024)

## Fellowship Alumni: Where Are They Now?



## Contact

Please contact current Fellows for any site-specific questions (contact information provided on subsequent pages).

For inquiries regarding general application or interview process, please contact:

Dhaval Patil, MS, BPharm  
Associate Director  
HEOR and Medical Access  
East Hanover, NJ  
dhaval.patil@novartis.com



# Novartis Pharmaceuticals Corporation/ Baylor Scott & White Health/ The University of Texas at Austin



---

## Fellowship Sites & Preceptors

### Baylor Scott & White Health

Paul Godley, PharmD, FASHP, BCPS, Director of Pharmacy, Ambulatory & Speciality Clinical Pharmacy Services, Temple, TX

### The University of Texas at Austin College of Pharmacy

Karen Rascati, RPh, PhD, FAPhA, Graduate Advisor, Eckerd/Turley Centennial Endowed Professor, Austin, TX

### Novartis Pharmaceuticals Corporation

Dhaval Patil, MS, BPharm, Associate Director, HEOR and Medical Access, East Hanover, NJ

---

## Baylor Scott & White Health/The University of Texas

Baylor Scott & White is an integrated healthcare system in central Texas. The Scott & White Health Plan is a health maintenance organization that has over 400,000 members and is affiliated with the Baylor Scott & White Quality Alliance, the system's accountable care organization, which represents over 6,000 physicians. Baylor Scott & White is affiliated with the College of Medicine, Texas A&M University Health Science Center, and the College of Pharmacy, The University of Texas at Austin.

The Department of Pharmacy at Baylor Scott & White provides progressive and innovative pharmaceutical services in a variety of environments for all components of the institution. Included are clinical and distributive services for the hospital, clinic and health plan, as well as sponsorship of pharmaceutical care programs and ambulatory care clinics focusing on lipid, diabetes and anticoagulation management. Fellows will gain significant understanding of the key issues involved in pharmacy services provided by prescription benefits management and managed care organizations. The integrated character of the institution and the Department of Pharmacy provides significant opportunities for pharmacy practice, research and education.

The Health Outcomes and Pharmacy Practice Division, College of Pharmacy, The University of Texas at Austin, is one of the preeminent educational institutions for pharmacy education in the nation. The college is located in downtown Austin, and the Fellow is offered the option of pursuing the Master of Science degree in Pharmaceutical Sciences at the University of Texas, Austin. The degree would be granted at the end of the Fellowship provided that the required coursework and thesis have been completed. The recommended course of study is designed to assist the Fellow in coordinating required and recommended coursework along with the Fellowship requirements. However, the coursework is tailored based on individual interests, background and career goals. Additionally, the College has a Center for Pharmacoeconomics Studies that currently has eight researchers on staff and conducts a variety of outcomes research studies each year.

The unique nature of the Baylor Scott & White integrated healthcare system, combined with the pharmacoeconomic expertise at the College of Pharmacy, offers significant opportunity for individuals interested in the Novartis Fellowship experience.

### Eligibility

*Eligible candidates must have a doctorate in pharmacy or the combination of an undergraduate degree in pharmacy plus an advanced degree in health services research, public health, health policy, pharmacy, economics, medicine or other related area. Experience in, or at a minimum, exposure to some aspect of outcomes research, health economics or another related field of research is preferred.*

### Information

*For questions or additional information, please contact:*

Ryan Thaliffdeen, PharmD  
Health Economics & Outcomes Research and  
Medical Access Fellow  
Email: ryan.thaliffdeen@bswhealth.org

All questions regarding potential visa sponsorship should be directed to the collaborating institution.



**First-Year Fellow:  
Ryan Thaliffdeen, PharmD**

Ryan Thaliffdeen is the first-year Health Economics & Outcomes Research (HEOR) Fellow with Novartis Pharmaceuticals Corporation, Baylor Scott & White Health (BSWH), and the University of Texas at Austin.

Ryan received his Doctor of Pharmacy degree from the University of California, San Francisco (UCSF). Ryan's interest in HEOR began his first-year of pharmacy school with his participation in the AMCP P&T competition and has continued to grow since then. He enters the Fellowship with a variety of past experiences including industry, consulting, and research.

During his time at UCSF, Ryan developed patient-reported outcomes disease area strategies and conceptual models as a Patient-Centered Outcomes Research intern at Genentech. After his role at Genentech, Ryan generated health economic evidence to support market access for clients at Coeus Consulting Group as a Patient Access and Value Associate. In addition to industry and consulting, Ryan has a background in outcomes research stemming from his previous role as a graduate research assistant at UCSF's Medication Outcomes Center, where he investigated real-world outcomes of CAR T-Cell Therapy Yescarta® (axicabtagene ciloleucel). Other relevant experiences include acting as president for the UCSF-AMCP chapter, a Global HEOR internship at AMCP/Allergan, volunteering for Medicare Part D Outreach, and serving as an AMCP National Student Pharmacist Committee member.

During his first year, Ryan collaborates with pharmaceutical companies to conduct outcomes research studies at BSWH, as well as supporting the Antibiotics Stewardship Committee and Specialty Task Force at BSWH. His current projects include outcomes research surrounding the implementation of a Deep Vein Thrombosis Treatment Bridge Clinic and an analysis of antibiotic prescription trends to help guide decision making at BSWH. Additionally, Ryan is working towards earning a Master's degree in Health Outcomes from the Division of Health Outcomes and Pharmacy Practice at the University of Texas at Austin.



**Second-Year Fellow:  
Cindy Nguyen, PharmD**

Cindy Nguyen is a second-year Health Economics & Outcomes Research (HEOR) and Medical Access Fellow with Novartis Pharmaceuticals Corporation, Baylor Scott & White Health (BSWH), and the University of Texas at Austin (UT Austin).

Cindy received her Doctorate of Pharmacy from the University of California, San Francisco (UCSF). She enters the Fellowship with complementary experiences in research, industry, health policy, managed care, pharmacy benefit management, specialty, and community pharmacy. Prior to the Fellowship, Cindy synthesized clinical evidence and health economic information to provide efficient access to data between manufacturers and healthcare decision-makers used for formulary evaluations at Xcenda®. She also worked at the Food and Drug Administration in the Office of Executive Programs, where she supported cross-functional committees regarding issues involving the opioid epidemic, exclusivity rights, and cannabis regulation. Her data analysis and quality improvement experience include drug utilization reviews for the Specialty Pharmacy at the University of California, Irvine Medical Center and a best practice alert audit that analyzed provider response to an antibiotic reassessment. Other relevant experience includes her role as a co-investigator at the UCSF Medication Outcomes Center, volunteer for the UCSF Medicare Part D Outreach, president for UCSF AMCP chapter, and a member of AMCP's National Student Pharmacist Committee.

During her first year, Cindy conducted outcomes research for pharmaceutical companies and supported the Antibiotics Stewardship Committee and Specialty Task Force at BSWH. She was able to work in a variety of projects utilizing electronic health record and retrospective claims data in multiple disease states, such as multiple sclerosis, hemophilia A, and rheumatoid arthritis. Some of her projects included financial analysis of specialty medications, assessing antibiotic prescribing trends to drive operational decisions at BSWH, and synthesizing a budget impact model for acute ischemic stroke. At BSWH and UT Austin, she was able to collaborate on diverse teams, including research faculty, physicians, and statisticians.

In her second year at Novartis, Cindy supports the US HE&OR Cardiovascular, Renal and Metabolic business unit. She works cross-functionally with internal and external stakeholders, working on various parts of a project from concept development to data dissemination dependent on strategic alignment. She is currently involved in multiple projects, including a retrospective claims analysis, preference study, and manuscript writing. In addition, Cindy is working towards earning a Master's degree in Pharmaceutical Science from the Division of Health Outcomes and Pharmacy Practice at the UT Austin.

# Novartis Pharmaceuticals Corporation/ Thomas Jefferson University, Jefferson College of Population Health



## Fellowship Sites & Preceptors

### Thomas Jefferson University

Vittorio Maio, PharmD, MS, MSPH, Research Professor, Director, Health Economics and Outcomes Research Fellowship, Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA

### Novartis Pharmaceuticals Corporation

Dhaval Patil, MS, BPharm, Associate Director, HEOR and Medical Access, East Hanover, NJ

## College of Population Health, Thomas Jefferson University

Established in 2008, the Jefferson College of Population Health (JCPH) is one of six colleges that comprise Thomas Jefferson University, founded in 1824 as Jefferson Medical College. JCPH builds upon the 18-year history of Jefferson's Department of Health Policy and specializes in all key areas of population health—public health, health policy, healthcare quality and safety, and applied health economics and outcomes research (AHEOR). The College has one of the oldest and most established outcomes research Fellowship programs in the country. To date, over 50 individuals have completed JCPH Fellowships and have successfully pursued careers in all sectors of the healthcare industry, including government, pharmacy, insurers and consulting.

During the first year, the Fellow will work in JCPH at the University's Philadelphia Center City campus and be assigned to manage specific outcomes research projects. As a member of the JCPH research team, s/he has the opportunity to attend and present at research meetings, journal clubs, Population Health Forums and sponsored educational programs. S/he may also contribute to any one of several graduate level classes taught by JCPH faculty in the College's public health, AHEOR, health policy, healthcare quality and safety, population health intelligence and population health graduate programs. The Fellow will develop writing skills through completion of a writing seminar, peer review of continuing education articles and authorship of manuscripts for publications edited by *American Journal of Medical Quality*, *Population Health Management*, and *Population Health Matters*.

Networking is also an important activity during the first year. The Fellow will interact with decision makers from both within the University and from a broad variety of organizations, including pharmaceutical and device manufacturers, health plans and other health-related employers. The Fellow will regularly meet with JCPH faculty and staff to discuss research projects and academic experiences, and s/he will be assigned a faculty mentor to coach him/her during the first year. Completion of master's level coursework through JCPH is a formal component of this Fellowship and serves to develop the knowledge and skills required for health economics and outcomes research. The Fellow has the option to complete a fully supported graduate Certificate or Master of Science degree program in public health, population health, population health intelligence, health policy or applied health economics and outcomes research.

The second year of training will take place at Novartis, located in East Hanover, New Jersey. During this time, under the guidance of a Novartis preceptor, the Fellow will work directly with the HEOR department at Novartis for a period of one year in order to further their educational objectives by gaining applied experience in health economics and outcomes research. In addition to project work, the Fellow will participate in meetings to share his or her work and further develop networking and presentation skills.

### Eligibility

*Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy, pharmacy administration or a related discipline. A background in pharmacy or medicine and experience in outcomes research, health economics or another related field of research is preferred. Candidates must have excellent written and verbal communication skills.*

### Information

*For questions or additional information, please contact:*

Jennifer Nguyen, PharmD  
Health Economics & Outcomes Research and  
Medical Access Fellow  
Email: jennifer.nguyen5@jefferson.edu

All questions regarding potential visa sponsorship should be directed to the collaborating institution.





**First-Year Fellow:  
Jennifer Nguyen, PharmD**

Jennifer Nguyen is the first-year Health Economics & Outcomes Research (HEOR) & Medical Access fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceuticals Corporation.

Jennifer Nguyen received her Doctor of Pharmacy from the University of Houston College of Pharmacy. Her interest in health economics & outcomes research stems from her passion for improving public health and promoting patient access, which were discovered through her experiences in research, industry, managed care, hospital, and specialty pharmacy.

Prior to her fellowship, Jennifer completed two internships in Janssen's Real World Value & Evidence team where she created budget impact models, a Tableau dashboard for data visualization of datasets, and conducted real-world evidence analyses. During her final year of pharmacy school, Jennifer completed a rotation with Humana where she provided clinical services for the Pharmacy & Therapeutics Committee with monthly drug reviews. During her specialty pharmacy rotation, Jennifer collaborated with various manufacturer's patient assistance programs to provide financial assistance to help underinsured patients access their medication. Her additional experiences include: serving multiple terms on IPHO's National Board, including her role as Chief National Student Officer, and advancing to the finalist round in the national AMCP P&T Competition three consecutive years.

At JCPH, Jennifer will be involved in a diverse array of projects including manuscript writing, claims based outcomes research, modeling, and PRO studies. Additionally, she will be working towards a master's degree in Applied Health Economics & Outcomes Research. Through the JCPH Fellowship, Jennifer aspires to build on her foundation of HEOR and related disciplines to improve the outcomes of patient care.



**Second-Year Fellow:  
Shivangi Patel, PharmD**

Shivangi Patel is a second-year Health Economics & Outcomes Research (HEOR) and Medical Access Fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceuticals Corporation.

Shivangi received her Doctor of Pharmacy Degree from the Philadelphia College of Pharmacy. Prior to the fellowship, Shivangi conducted academic research analyzing electronic health record data within disease states like pneumococcal infections and neuromuscular disorders. She gained exposure to HEOR during her rotation at Mallinckrodt Pharmaceuticals, where she conducted a literature review on the unmet needs and disease burden of the hepatorenal syndrome patient population.

During the first year of her fellowship, Shivangi furthered her training in HEOR through involvement in outcomes research projects analyzing insurance claims data, electronic health record data, and patient registry data. She led projects in employer perspectives, anti-diabetic medication adherence, leukemia, and brain cancer treatment patterns. She participated in the planning and implementation stages of research projects including protocol development, research analysis plan, and project timelines. Shivangi was acquainted with the hospital formulary decision making process by participating in institutional level meetings such as the P&T Committee and Pharmacoeconomics and Comparative Effectiveness Committee. Shivangi had the opportunity to become a published author in the American Journal of Medical Quality and presented 4 research projects at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 conference.

During the second year of her fellowship, Shivangi supports the US HEOR New Products team by managing research studies through collaboration with cross-functional teams in concept development, protocol review, and strategic planning. Her research consists of retrospective claims database analyses, qualitative research, and economic modeling. Shivangi is also continuing her coursework towards earning a Master's degree in Applied Health Economics and Outcomes Research from JCPH.

# Novartis Pharmaceuticals Corporation/ University of Maryland School of Pharmacy (not recruiting for 2022-2024)



## Fellowship Sites & Preceptors

### University of Maryland School of Pharmacy

Not recruiting for 2022-2024

### Novartis Pharmaceuticals Corporation

Dhaval Patil, MS, BPharm, Associate Director, HEOR and Medical Access, East Hanover, NJ

## The University of Maryland School of Pharmacy

The University of Maryland School of Pharmacy, founded in 1841, is the fourth oldest school of pharmacy in the nation. The School of Pharmacy is one of seven professional schools and a graduate school located at the University of Maryland Baltimore, a thriving center for health services practice and research. Through its education, research and service programs, the School of Pharmacy strives to improve the health and well-being of society by aiding in the discovery, development and optimal use of medicines. One of three departments within the School, the Department of Pharmaceutical Health Services Research (PHSR) aims to improve the health of diverse populations through pharmaceutical health services research, education, service and community outreach.

PHSR scholarship spans the disciplines of behavioral sciences, pharmacoeconomics, pharmacoepidemiology and policy. Fifteen faculty members conduct research sponsored by federal and state governmental agencies, foundations and the pharmaceutical industry. Work clusters around issues inherent in the Department's Centers: The Peter Lamy Center on Drug Therapy and Aging, and the Center on Drugs and Public Policy. Pharmaceutical Research Computing, a third Departmental center, provides computer programming, data management and analytic support to faculty, students and staff.

The Department houses numerous comprehensive databases, including the Chronic Condition Warehouse (CCW) 5% sample of Medicare beneficiaries linked to Part D data; the Medicare Current Beneficiary Survey; Medicaid and MAX data; IQVIA dataset and other proprietary and public data sets.

This two-year Fellowship focuses on the development of research skills relevant to health policy, with a particular focus on pharmaceutical policy. Fellows will spend the first year at the University of Maryland Baltimore honing research and policy skills and the second year at Novartis, where they will apply training and interests in an industry environment. Broad domains of interest include research focusing on medication management and outcomes in geriatric patients suffering multiple chronic illnesses, Medicare policy, long-term-care policy, mental health policy, COVID-19, patient-centered outcomes research and comparative effectiveness research. The successful applicant will work closely with a mentoring team to identify relevant research areas and training opportunities. The unique combination of rigorous academic training with industry experience in the second year will provide the Fellow considerable experience to conduct policy-relevant health services and outcomes research.

### Eligibility

*Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy, pharmacy administration or a related discipline. A background in pharmacy or medicine and experience in outcomes research, health economics or another related field of research is preferred. Candidates must have excellent written and verbal communication skills.*

### Information

*For questions or additional information, please contact:*

Aaron Carabajal, PharmD  
Health Economics & Outcomes Research and  
Medical Access Fellow  
Email: acarabajal@rx.umaryland.edu

All questions regarding potential visa sponsorship should be directed to the collaborating institution.



### **First-Year Fellow: Aaron Carabajal, PharmD**

Aaron Carabajal is the first-year Health Economics & Outcomes Research (HEOR) and Medical Access fellow at the University of Maryland School of Pharmacy and Novartis Pharmaceuticals Corporation.

Aaron received his Doctor of Pharmacy degree from the University of Texas at Austin and brings to the fellowship his valuable experiences from industry, managed care, research, hospital, and community pharmacy. Prior to the fellowship, he supported the Medical Affairs and HEOR teams at AstraZeneca by conducting an analysis of oncology pathway organizations and their effectiveness at reducing healthcare costs while providing optimal treatment strategies for patients. His managed care experience includes monitoring drug usage and cost trends, performing pharmacoeconomic analyses, and synthesizing clinical evidence to support the Department of Defense (DOD) formulary management of SGLT2 inhibitors in the treatment of heart failure. His data analysis and quality improvement experiences include drug utilization reviews of antidiabetic and antihypertensive medications for the DOD Pharmacy & Therapeutics Committee, and analyzing retrospective claims data to assess for cost-saving opportunities at the Veteran's Administration. Additionally, Aaron successfully completed research at UT analyzing polypharmacy in a high-risk elderly population using retrospective patient-reported data to assess for potentially inappropriate medication use.

During his first year at the University of Maryland, Aaron supports Dr. Linda Wastila and her team in conducting research pertaining to health policy and outcomes research in vulnerable populations. His current projects involve analyzing antipsychotic over-use in long-term care facilities and COVID-19 vaccination trends among nursing home residents and staff. During his first year of fellowship, Aaron will focus on further developing his research methodology and analytic techniques by completing a Master's degree in Pharmaceutical Outcomes & Policy with a focus in pharmacoeconomics at the University of Florida.



### **Second-Year Fellow: Alexandra Wallem, PharmD, MS**

Alexandra Wallem is the second-year Health Economics & Outcomes Research (HE&OR) and Medical Access Fellow with the University of Maryland School of Pharmacy (UMB) and Novartis Pharmaceuticals Corporation.

Alex graduated with her Doctor of Pharmacy and Master of Pharmaceutical Sciences Institute for Pharmaceutical Outcomes and Policy (IPOP) degrees from the University of Kentucky in Lexington. Alex served as the Vice President of Phi Lambda Sigma Pharmacy Leadership Society and Lambda Kappa Sigma, Professional Pharmacy Fraternity, during pharmacy school. Her passion for pharmacoconomics and health outcomes is rooted in her interest in public health and policy. This interest was sparked during her second year of pharmacy school while she developed board approved protocols for emergency contraception allowing pharmacists to improve access to care in rural areas. Alex's research concentration for her master's degree investigated medication use in older adults with dementia resulting in two publications.

During her final year of pharmacy school, Alex completed rotations with a policy and research focus at Eli Lilly and Company and the National Health Services (NHS) Lothian in Edinburgh, Scotland. At Eli Lilly, she completed projects supporting migraine and cluster headache therapeutics. Additionally, at the NHS, Alex successfully completed research exploring variation in applying a clinical pharmacy risk stratification tool.

During her first year of fellowship, Alex focused on further developing her research methodology and analytic techniques through additional UMB PhD level coursework and completion of a HEOR certificate from the University of Washington. She improved upon her communication skills through student organization mentorship, such as IPhO and AMCP, and becoming a teaching assistant for two UMB pharmacy courses. At the University of Maryland, Alex supported Dr. Linda Wastila and her team with project development, manuscript writing, and data analysis in research involving older adults, transitions of care, and antipsychotic overuse in long-term care facilities. Additionally, she lead research investigating nursing home characteristics, such as race, staffing shortages, and vaccinations, influence on COVID-19 outcomes. As a result, Alex is in the process of publishing five manuscripts.

In her second year at Novartis, Alex supports the US HE&OR Immunology, Hepatology & Dermatology team. She works cross-functionally with internal and external stakeholders, including academic medical centers, working on various stages of project development, strategic alignment, and concept messaging. She is currently involved in projects, including retrospective claims, electronic health records, targeted literature reviews, and economic modeling. In addition, Alex is further developing her analytic knowledge by pursuing a certificate in data science from Johns Hopkins.

## Previous Fellows

### **Neetu Agashivala, MS**

Global RWE Head, Cardiovascular Renal Metabolism, Novartis

### **Lauren Bartolome, PharmD**

Senior Manager, Health Economics & Outcomes Research, Pfizer

### **Kelly Fee Bell, PharmD, MSPhr**

Value Evidence Lead, GlaxoSmithKline

### **William Boyko, PharmD**

Consultant Pharmacist, P&C Pharma

### **Cat Bui, PharmD**

Director, Health Economics & Outcomes Research, AbbVie Pharma US, Inc.

### **Scott Bull, PharmD**

Director, Clinical Development, Johnson & Johnson Pharmaceutical Research & Development

### **Beilei Cai, PhD, MA**

Senior Director, Oncology HEOR, Novartis

### **Jane Chang, MPH**

Senior Director, US Oncology HEOR, Pfizer

### **Michelle Choi, PharmD**

Medical Science Liaison, Sanofi

### **Grace Chun, PharmD**

WW Scientific Content and US Market Capabilities Manager, Bristol-Myers Squibb

### **Paul C. Cockrum, PharmD, DPh**

National Director, Field HEOR, Celgene

### **Arijita Deb, PhD**

Associate Director, Merck

### **Laurence Djatche, PharmD, MS**

Associate Director, Outcomes Research, Center of Observational and Real-World Evidence (CORE), Merck

### **QuynhChau Doan, MS, RPh, PhD**

HEOR, AbbVie

### **Batul Electricwala, PhD**

Associate Director, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation

### **John Fastenau, PhD, MPH, RPH**

Senior Director, Patient Reported Outcomes, Janssen Pharmaceutical Companies of Johnson & Johnson

### **Feride Frech-Tamas, PhD, MPH**

Executive Director, Epidemiology and Outcomes Research, Lexicon Pharmaceuticals

### **Rahul Garg, PhD**

Assistant Professor, Chicago State University

### **Joseph Goble, PharmD**

Principal Scientific Account Lead, Real World Value & Evidence Scientific Exchange, Janssen

### **Boris Gorsh, PharmD**

Director, Value Evidence and Outcomes, GlaxoSmithKline

### **Geneen Graber, PharmD**

President and CEO, Dr. G's Pharmacy

### **Bill Grant, PhD**

Associate Professor of Economics, College of Business, James Madison University

### **Amy Grogg, PharmD**

President, Parabolam, LLC

### **Kristy Hanson, PharmD, MS**

Scientific Consultant, United BioSource Corporation

### **Peter Hur, PharmD, MBA**

Director, Worldwide HEOR Inflammation and Immunology, Pfizer

### **Tom Karagiannis, PharmD, MS**

Director, Global Market Access and Pricing, Abbvie

### **Jennifer Kim, PharmD**

Director, Global Price and Reimbursement, AstraZeneca

### **John Kim, PharmD**

Executive Director, Head of Global Market Access, Seattle Genetics

### **Nina Kim, PharmD, MS**

Manager, HEOR Strategy and Evidence Generation, Novo Nordisk

### **Yoona Kim, PharmD, PhD**

Co-founder and CEO, Arine

### **John Ko, PharmD, MS**

Value & Evidence Strategy Director and Global Medical Director, Alnylam

### **Amy Law, PharmD, MS**

Director, Medical Affairs Research, Intercept Pharmaceuticals

### **Junji Lin**

Associate Director, Jazz Pharmaceuticals

### **Jackie Lu, PharmD, MS**

Executive Director of Marketing, Pacira Pharmaceuticals

**Mario Luong, PharmD, MPH**

Associate Director of Operations,  
UnitedHealth Group

**Jeannie Menz, PharmD**

Director, Content Development and Training,  
Sandoz

**Gilbert C. Ngan**

Pharmacist: Part D Benefits Analyst,  
CMS

**Lina Nol-Heiring, MBA, RPh**

Senior Territory Manager,  
Ortho Dermatologics

**Engels Obi, PhD**

Director, Global Outcomes Research,  
Merck

**Jacqueline B. Palmer, PharmD**

Associate Director, Peer to Peer Marketing  
Novartis

**Jina Park, PharmD**

Director, Advanced Analytics,  
Komodo Health

**Siyeon Natalie Park, PharmD**

Staff Scientist  
Geisinger

**Hoa T. Pham**

Senior Director, Field HEOR,  
Beigene

**Ngan Pham, PharmD**

Senior Manager, HEOR and Value Strategy  
Theravance Biopharma, US Inc.

**Craig Plauschinat, PharmD, MPH**

Director, HEOR & RWE,  
Eisai, Inc.

**Shibani Pokras, MPH**

Senior Director, Oncology Cell Therapy,  
GlaxoSmithKline

**Karim Prasla, PharmD, MS**

Vice President, Clinical Outcomes  
Analytics and Research,  
Magellan Health Services

**Karina Raimundo, MS**

Director, HEOR,  
Genentech, Inc.

**Swetha Raparla**

Analytics Consultant,  
Cigna

**David Ray, PharmD, MBA, MPH**

Senior Director, Head of US HEOR  
Ipsen Biopharmaceutical

**Rahul Sasané, PhD, MS, BPharm**

Head – Global HEOR-RWE & Reimbursement,  
Cerevel Therapeutics, LLC

**Veronica Sendersky, PharmD**

Managing Director,  
Excellentia Pharma Consulting

**Karishma Shelley, PharmD**

Manager, HEOR Strategy and Evidence  
Generation Novo Nordisk

**Hemal Shah, PharmD**

President/Founder,  
Value Matters, LLC

**Slaven Sikirica, MS**

Director, US HEOR Hematology  
Pfizer, Inc

**Anh Singhanian, PharmD**

Senior Director, HEOR and Medical Publications,  
Summit Therapeutics

**Liz Stanley Smart, MPH**

Associate Director, Health Economics & Outcomes  
Research,  
Boehringer Ingelheim

**Bhavini Patel Srivastava, BSPS, MS**

Associate Director, Global Value and HEOR  
Jazz Pharmaceuticals

**Kangho Suh, PharmD, MS**

Assistant Professor,  
University of Pittsburgh

**Dusica Tasic**

Health Economics Manager, Global Marketing,  
GE Healthcare

**Devi Thaker, PharmD**

Director, PharmacoAnalytics,  
GlaxoSmithKline

**Melody Tran, PharmD, MS**

Medical Outcomes Liaison,  
Abbott Laboratories

**Yuen Tsang, PharmD, MPH**

Senior Medical Liaison, Managed Markets and Health  
Economics & Outcomes Research,  
Actelion Pharmaceuticals

**Stuart Turner, BPharm, MPH**

Executive Director Global Real World Evidence  
& Data Science  
Novartis

**Stefan Varga, PharmD, MS**

Director, Outcomes Research,  
Merck

**Ashok Vegesna, PharmD, MS**

Director, National Accounts,  
Novartis Gene Therapies

**Joel Wallace, PharmD, MPH, MBA**

Head, Global HEOR, Market Access and Business  
Strategy, Exelixis

**Pin Xiang, PharmD**

Sr Associate Director in HEOR Value Evidence  
and Outcome Liaison  
Boehringer Ingelheim

**Esther Yi, PharmD, MS**

Associate Director, HEOR, Medical Access Novartis

**Krista Yokoyama, PharmD**

Senior Manager, Pharmacy Analytics,  
Blue Shield of California



# HEOR and Medical Access Fellowship Application Form

Please type or print

Date \_\_\_\_\_

Name: \_\_\_\_\_  
Last First MI

Address: \_\_\_\_\_  
Street City State Zip Code

Phone: \_\_\_\_\_  
Primary Secondary

Email: \_\_\_\_\_

Undergraduate and Graduate Degree(s) (date received or expected):

\_\_\_\_\_  
\_\_\_\_\_

## 2-Year Programs (Preferred Degrees: PharmD, PhD, MS)

Please check any site(s) of interest:

\_\_\_\_\_ Baylor Scott & White Health/The University of Texas at Austin/Novartis Pharmaceuticals Corporation  
\_\_\_\_\_ Thomas Jefferson University College of Population Health/Novartis Pharmaceuticals Corporation

## Application Process (rolling submission, application deadline is October 22<sup>nd</sup>, 2021 at 11:59 pm EDT):

To apply, please email [dhaval.patil@novartis.com](mailto:dhaval.patil@novartis.com) and include the following materials:

- Cover Letter
- CV
- Include first-year fellowship site (or sites)
- Email of 2 References

If offered an interview, the following documents will be requested:

- 2 Letters of Recommendation (sent via email from references)
- Unofficial Transcript

## Requirements:

Graduate degree in a relevant discipline focused on pharmacy, health services research, health economics, epidemiology, or a related discipline (e.g., PharmD, PhD, MPH, etc.). A background in pharmacy or medicine and experience in outcomes research, health economics, or another related field of research is preferred. Excellent communication skills (oral and written). Demonstrated success in working in teams and independently.

## Please email or send the required application materials to:

Email: [dhaval.patil@novartis.com](mailto:dhaval.patil@novartis.com)

